Non-Alcoholic Steatohepatitis (NASH) Market Size, Share, Growth and Industry Report

<p>The global non-alcoholic steatohepatitis (NASH) market size reached US$ 1.6 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 11.5 Billion by 2032, exhibiting a growth rate (CAGR) of 24.18% during 2024-2032. The rising prevalence of NASH, increasing awareness regarding early diagnosis and treatments, and the integration of artificial intelligence (AI) and machine learning (ML) technologies represent some of the key factors driving the market.</p>

<table align="center" border="1" cellpadding="1" cellspacing="1" dir="ltr" style="width:100%">
<thead>
<tr>
<th scope="col" style="width:70%">
<div style="text-align:left">Report Attribute&nbsp;</div>
</th>
<th scope="col">
<div style="text-align:left">Key Statistics</div>
</th>
</tr>
</thead>
<tbody>
<tr>
<td>
<div><strong>Base Year</strong></div>
</td>
<td>
<div>2023</div>
</td>
</tr>
<tr>
<td>
<div><strong>Forecast Years</strong></div>
</td>
<td>
<div>2024-2032</div>
</td>
</tr>
<tr>
<td>
<div><strong>Historical Years</strong></div>
</td>
<td>
<div>2018-2023</div>
</td>
</tr>
<tr>
<td>
<div><strong>Market Size in 2023</strong></div>
</td>
<td>US$ 1.6 Billion</td>
</tr>
<tr>
<td>
<div><strong>Market Forecast in ​​​​​​​2032</strong></div>
</td>
<td>US$ 11.5 Billion</td>
</tr>
<tr>
<td><strong>Market Growth Rate ​​​​​​​2024-2032</strong></td>
<td>24.18%</td>
</tr>
</tbody>
</table>

<p>IMARC Group provides an analysis of the key trends in each segment of the global non-alcoholic steatohepatitis (NASH) market, along with forecasts at the global, regional, and country levels from 2024-2032. Our report has categorized the market based on drug type, disease cause, sales channel, and end user.</p>

<p>全球非酒精性脂肪性肝炎（NASH）市场规模于2023年达到16亿美元。展望未来，IMARC集团预测该市场规模将在2032年增长至115亿美元，预计在2024-2032年期间实现24.18%的复合年增长率。NASH患病率的上升、对早期诊断和治疗的认知度提升，以及人工智能（AI）和机器学习（ML）技术的融合，是推动市场增长的关键因素。</p>

<table align="center" border="1" cellpadding="1" cellspacing="1" dir="ltr" style="width:100%">
<thead>
<tr>
<th scope="col" style="width:70%">
<div style="text-align:left">报告属性</div>
</th>
<th scope="col">
<div style="text-align:left">关键统计数据</div>
</th>
</tr>
</thead>
<tbody>
<tr>
<td>
<div><strong>基准年</strong></div>
</td>
<td>
<div>2023</div>
</td>
</tr>
<tr>
<td>
<div><strong>预测年份</strong></div>
</td>
<td>
<div>2024-2032</div>
</td>
</tr>
<tr>
<td>
<div><strong>历史年份</strong></div>
</td>
<td>
<div>2018-2023</div>
</td>
</tr>
<tr>
<td>
<div><strong>2023年市场规模</strong></div>
</td>
<td>16亿美元</div>
</td>
</tr>
<tr>
<td>
<div><strong>2032年市场规模预测</strong></div>
</td>
<td>115亿美元</div>
</td>
</tr>
<tr>
<td><strong>2024-2032年市场增长率</strong></td>
<td>24.18%</div>
</td>
</tr>
</tbody>
</table>

<p>IMARC集团对全球非酒精性脂肪性肝炎（NASH）市场的各个细分市场趋势进行了分析，并从2024-2032年对全球、区域和国家层面的市场进行了预测。我们的报告根据药物类型、疾病原因、销售渠道和最终用户对市场进行了分类。</p>